Abstract | The tumour microenvironment is the primary location in which tumour cells and the host immune system interact. Different immune cell subsets are recruited into the tumour microenvironment via interactions between chemokines and chemokine receptors, and these populations have distinct effects on tumour progression and therapeutic outcomes. In this Review, we focus on the main chemokines that are found in the human tumour microenvironment; we elaborate on their patterns of expression, their regulation and their roles in immune cell recruitment and in cancer and stromal cell biology, and we consider how they affect cancer immunity and tumorigenesis. We also discuss the potential of targeting chemokine networks, in combination with other immunotherapies, for the treatment of cancer.
Chemokines are small, secreted proteins that are best known for their roles in mediating immune cell traffick ing and lymphoid tissue development 1,2 . The chemo kines are the largest subfamily of cytokines and can be further subdivided into four main classes depending on the location of the first two cysteine (C) residues in their protein sequence: namely, the CCchemokines, the CXCchemokines, Cchemokines and CX 3 C chemokines 2 . There is an important degree of redun dancy in the chemokine superfamily, with many ligands binding different receptors and vice versa 2 (FIG. 1) . In the tumour microenvironment, chemokines can be expressed by tumour cells and other cells, including immune cells and stromal cells. In response to specific chemokines, different immune cell subsets migrate into the tumour microenvironment and regulate tumour immune responses in a spatiotemporal manner. In addition, chemokines can directly target non immune cells -including tumour cells and vascular endo thelial cells -in the tumour microenvironment, and they have been shown to regulate tumour cell pro liferation, cancer stem-like cell properties, cancer invasive ness and meta stasis. Therefore, chemokines directly and indirectly affect tumour immunity; shape tumour immune and biological phenotypes; and influence can cer progression, therapy and patient outcomes [3] [4] [5] [6] [7] [8] [9] [10] (FIG. 1) .
In this Review, we describe the expression patterns and regulation of the main chemokines that are found in the human cancer microenvironment, and their effects on immune cells and nonimmune cells. There has recently been a huge amount of research on cancer immunology and immunotherapy 10, 11 , and here we discuss whether selectively targeting chemokine-chemokine receptor signalling could complement and increase the efficacy of the immunotherapies that are currently being used in cancer treatment 3, 4, 10, 12 .
Immune cell tumour trafficking Different lymphocytes traffic into the tumour micro environment, and they can modulate tumour immune responses in both primary tumours and metastatic sites. Here, we discuss several key chemokine networks that regulate lymphocyte recruitment into the tumour microenvironment, and discuss how the recruited lymphocyte subsets regulate tumour immunity and tumorigenesis.
The recruitment of effector T cells and natural killer cells. CD8
+ T cells that are specific for tumour associated antigens (TAAs) can engage tumour cells in an antigenspecific manner, and they drive antitumour immunity by secreting effector cytokines, releasing cytotoxic molecules (such as granzyme B and perforin) and inducing apoptosis in tumour cells. In addition to CD8 + T cells, interferonγ (IFNγ)expressing T helper 1 (T H 1) cells and natural killer (NK) cells have potent antitumour effects in the tumour microenvironment. Effector CD8 + T cells, T H 1 cells and NK cells express CXCchemokine receptor 3 (CXCR3), which is the receptor for the T H 1type chemokines CXCchemokine ligand 9 (CXCL9) and CXCL10, and they can migrate into tumours in response to these chemokines (FIG. 2) . Increased levels of CXCL9 and CXCL10 are associated with increased numbers of tumourinfiltrating CD8 + T cells, and correlate with decreased levels of cancer metastasis and improved survival in patients with ovar ian cancer and colon cancer [13] [14] [15] [16] [17] [18] . Recent studies have demonstrated that tumourinfiltrating CD8 + T cells and intratumoural T H 1type chemokines are associated with positive responses to therapeutic blockade of the immune checkpoint molecules programmed cell death protein 1 (PD1) and PD1 ligand 1 (PDL1; also known as B7H1) 10 . Interestingly, CD8 + T cells in the tumour microenvironment were shown recently to regulate the metabolism of the chemotherapeutic agent cisplatin by fibroblasts in ovarian cancer 19 . In this study, CD8 (REFS 17, (20) (21) (22) . These homing molecules may be associated with The chemokine receptors and ligands that belong to each of the main chemokine families (namely, the C-, CC-, CXC-and CX 3 C-chemokine families) are shown. Blue and red boxes represent chemokine-chemokine receptor interactions that occur in mice and humans, respectively, and the non-boxed interactions occur in both humans and mice. Abbreviations enclosed in parentheses indicate alternative names for the preceding chemokine or chemokine receptor. Question marks indicate that the respective chemokine receptor is currently unknown. T reg cells can be mobilized from the bone marrow into the periphery by granulocyte colonystimulating factor (GCSF), which promotes the degradation of CXCL12 CXCR3 (REF. 46 ). CCL2 mediates the trafficking of type I NKT cells into neuroblastomas 47, 48 . NKT cell trafficking into other types of tumour is poorly studied.
The recruitment of B cells. Human tumourinfiltrating B cells have been less wellstudied than have effector T cells 49 . B cells express CXCR4 and may be recruited by CXCL12 into the cancer microenvironment. High levels of tumourinfiltrating B cells are associated with a survival advantage in breast cancer 50 , highgrade serous ovarian cancer 51 and cervical cancer 52 . B cells may also be present in tumourassociated tertiary lymphoid structures 53 and increase T cell responses by releasing cytokines and chemokines, by serving as antigenpresenting cells (APCs) and by producing anti bodies. However, mouse studies indicate that B cells may negatively regulate tumour immunity and promote tumour progression via IL10 and transforming growth factorβ (TGFβ) expression [54] [55] [56] . Furthermore, by acti vating Fcγ receptors (FcγRs) on myeloid cells and mast cells, B cells can promote tumour angio genesis and the recruitment of tumourpromoting immune cells [54] [55] [56] . There may be different subsets of B cells, including regulatory B cells 57 ; however, it is unknown whether different B cell subsets are recruited into the tumour microenvironment by different chemokines, and whether they have differential roles in human tumour immunity and tumorigenesis.
In summary, different lymphocyte subsets are recruited into the tumour microenvironment by dis tinct chemokine-chemokine receptor signalling path ways. Effector T cells, NK cells and perhaps NKT cells may mediate an antitumour immunity, whereas T reg cells, T H 22 cells and perhaps B cells may promote tumorigenesis.
Chemokines and tumour-associated APCs
APCs -including DCs, macrophages, B cells (discussed above) and perhaps myeloidderived suppressor cells (MDSCs) -are recruited into the tumour microenvironment; they regulate antitumour immunity by interacting with T cells, and affect tumori genesis by interacting with tumour (stemlike) cells and stromal cells.
The recruitment of myeloid DCs to tumours. Mature myeloid DCs can drive potent antitumour immune responses by priming and activating TAAspecific T cells 58 . By contrast, immature myeloid DCs are poor mediators of T cell activation and can induce T H 2type immune responses 27, 59 , which may support tumour progression. Immature myeloid DCs, but not mature myeloid DCs, are found in breast cancer and the can cer stroma 27, 60 . Immature DCs express CCR6 and are recruited into tumours in response to tumourderived CCL20 (REFS 27, 60) . However, in experimental mouse models, the overexpression of CCL20 (REF. 25, 64 . Furthermore, these regulatory CD8 + T cells express CCR7, and may home to the draining lymph nodes and suppress TAAspecific T cell priming 64 . In addition, plasma cytoid DCs can promote tumour angiogenesis 65 . Thus, the recruitment of plasma cytoid DCs into the human tumour micro environment by CXCL12 may support the develop ment of an immunosuppressive site that is permissive for tumour progression.
The recruitment of macrophages. Macrophages can be recruited into the tumour microenvironment by CCL2-CCR2 signalling 66 . CCL2 expression by tumours correlates with the numbers of tumour associated macro phages (TAMs) in many tumours and is asso ciated with poor patient prognosis in some cancers, including breast cancer 67 . TAMs may inhibit TAA specific T cell activation via the expression of inhibi tory B7 family members, including PDL1 and B7H4 (also known as VTCN1), and through the induction of the galectin 9-T cell immunoglobulin mucin 3 (TIM3) pathway [68] [69] [70] [71] . Furthermore, TAMs support chemo resistance 72 , and promote cancer stemness and meta stasis 67, 73 . CCL2 can also activate metastasis associated macrophages to secrete CCL3, which further promotes macrophage retention in the tumour and tumour meta static sites 74 . The CCL5-CCR5 pathway may be an additional chemo attractant signalling axis that affects macrophages in breast cancer. Increased CCL5 expression correlates with more advanced stages of breast cancer 75, 76 . Thus, the recruitment of macro phages into the tumour micro environment may pro mote tumour progression. However, different subsets of macrophages 77 and macrophages in different matura tion stages may have diverse functions in tumours 71, 78, 79 . For example, CD68
+ macrophages are associated with improved survival among patients with colon cancer 79 .
CD169
+ macro phages can mediate TAAspecific T cell crosspriming in tumourdraining lymph nodes, and initiate and promote tumour immunity in a mouse model 80 . Furthermore, macrophages can either increase or antagonize the antitumour efficacy of cytotoxic chemotherapy, cancercell targeting antibodies and immunotherapeutic agents 81 . Thus, targeting macro phages by the manipulation of chemo kine-chemokine receptor signalling as a therapeutic approach may need to take these effects into account. 73, [86] [87] [88] . Monocytic MDSCs (macrophages) can be recruited into the tumour microenvironment by CCL2 (REFS 74, 89) . The CXCL5-CXCR2 and CXCL12-CXCR4 signalling pathways are also reported to be involved in MDSC trafficking in a breast tumour mouse model 90 . CXCL8 regulates granulocytic MDSC migration and degran ulation via CXCR1 and CXCR2 signalling 91 . Tumour cells and myeloid cells express CXCL8, and recruit neutrophils into the tumour microenvironment 91 . Certain subsets of T reg cells in the human cancer micro environment express CXCL8 and promote neutro phil migration into tumours 43 . Neutrophils secrete various molecules that support and promote tumour angio genesis. Thus, the recruitment of neutrophils by CXCL8 is generally thought to promote tumour progression and metastasis 91, 92 . In summary, distinct chemokines mediate the recruitment of different APC subsets into the tumour microenvironment, and these APCs differentially regu late tumour immunity and cancer progression. In addi tion to targeting immune cells, chemokines can also affect tumorigenesis by directly targeting tumour cells and tumour stromal cells.
Effects of chemokines on tumour cells
Chemokines can directly and indirectly target tumour stemlike cells and stromal cells in tumours. Below, we discuss how different chemokine-chemokine receptor signalling pathways affect tumour cell proliferation, stemness and angiogenesis to ultimately alter tumour metastasis and disease outcomes in patients (TABLE 1) .
Direct pro-tumour effects of chemokines. CCL2, CCL3 and CCL5 can promote tumour invasion and meta stasis. CCL2 targets vascular endothelial cells via the Janus kinase 2 (JAK2)-STAT5 and p38 mitogen activated protein kinase pathways 93 , and affects tumour vas cularization [94] [95] [96] and tumour metastasis 93 . CCL2, CCL3 and CCL5 can induce matrix metallo proteinase 9 (MMP9) secretion by monocytes 76, 97 ; MMP9, by degrading the matrix, allows for tumour cell extra vasation 98 . Furthermore, CCL2 and CCL5 can promote cancer cell proliferation, survival, motility 99 , epithelialmesenchymal transition (EMT) and stemness [100] [101] [102] [103] . In addition, these chemo kines recruit MDSCs and macro phages into the tumour microenvironment, and in turn, promote and sustain human cancer stemness 73, 86, 88, 104 . CCL18 can directly influence tumour cells by, for example, promoting invasion, metastasis and EMT in breast cancer, pancreatic cancer, ovarian cancer and prostate cancer [105] [106] [107] [108] [109] . However, the effect of CCL18 seems to depend on the cancer type, as high levels of CCL18 are a good prognostic factor in gastric can cer 110 . CCL18 inhibits cutaneous T cell proliferation 111 . In some cancers, such as breast cancer, the main source of CCL18 in the tumour is TAMs, whereas ovarian cancer cells can overexpress CCL18 (REFS 105, 106) . Although not shown in cancer, CCL18 has an immuno suppressive effect on DCs and macrophages [112] [113] [114] [115] . CCL18conditioned APCs may induce the differen tiation of T reg cells, leading to immunosuppression. This CCL18driven immunosuppression might exist in the tumour microenvironment [112] [113] [114] [115] . The receptor for CCL25, CCR9, is highly expressed in many cancers. CCR9 signalling in tumour cells increases their resistance to chemotherapy 116, 117 and their expres sion of MMPs, which promote cancer invasion and metastasis [118] [119] [120] [121] [122] . CCL25 can also promote metastasis by recruiting CCR9
+ cancer cells into CCL25expressing tissues, such as the small intestine. For example, cutaneous melanoma cells, and possibly adult lymphoblastic leukae mia cells, preferentially metastasize to the small intestine owing to signalling via the CCR9-CCL25 axis [123] [124] [125] . CXCL8 targets vascular endothelial cells and regu lates angiogenesis by promoting endothelial cell sur vival 126 . CXCL8 targets cancer cells; promotes cancer invasion and migration 127 ; induces tumour premature senescence 128 ; contributes to hypoxiainduced tumour apoptosis resistance 129 ; and promotes EMT 130 and cancer stemness [131] [132] [133] [134] [135] . Thus, CXCL8 signalling is important in cancer cell biology.
CXCL12 targets vascular endothelial cells and synergizes with vascular endothelial growth fac tor (VEGF) to promote tumour angiogenesis 26, 136 . CXCL12 can also promote tumour cell proliferation and survival 63, 137 . Furthermore, the CXCL12-CXCR4 signalling pathway promotes cancer cell invasion and metastasis [138] [139] [140] [141] [142] [143] . It has been suggested that CXCR4 + tumour cells may have stemlike properties, have a high metastatic potential and show radiation resist ance [144] [145] [146] . Thus, the CXCL12-CXCR4 signalling pathway has a role in tumour proliferation, meta stasis and stemness. CXCL12 can also bind to CXCR7 (REFS 147, 148) . Although considered a decoy and scavenger receptor [147] [148] [149] , CXCR7 can signal through nonGproteinmediated mechanisms in cancer cells and endothelial cells, including tumourassociated endothelial cells 150, 151 . Its role as a standalone G pro teincoupled receptor is still under debate, but it can bind to CXCR4 and mediate signalling through intra cellular CXCR4 signalling molecules, a process impli cated in the chemotaxis of T cells 147, 152 . As mentioned above, cancer cells express CXCR7, which can promote the adhesion, invasion, survival and growth of prostate cancer 153, 154 , breast cancer 148, 150 , and lung cancer cells 150 . CXCR7 signalling can also indirectly contribute to angiogenesis by increasing the expression of CXCL8 and VEGF in prostate cancer cells 153 . CXCL14 (also known as BRAK) has been reported to be involved in tumorigenesis. Interestingly, the effect of CXCL14 in different cancers varies. Cancers such as those of pancreas 155 and prostate 156 show increased CXCL14 expression, whereas other types of cancerincluding breast cancer, kidney cancer, cervical cancer, and head and neck cancer -consistently lose expres sion of CXCL14 . In line with this, the overexpression of CXCL14 in breast tumours that lack CXCL14 or even in tumour myoepithelial cells leads to reduced tumour growth, metastasis and invasion 158, 161 . Even though the receptor for CXCL14 is still unknown, in vivo loss of CXCL14 is correlated with reduced DC loss in a head and neck squamous cell carcinoma mouse model 62 . CXCL17 is highly expressed in various cancer cells, recruits granulocytic MDSCs into the tumour, and increases tumour growth partially by increasing angio genesis 162, 163 . Indeed, CXCL17 induces VEGF expression in monocytes and endothelial cells 163, 164 . As CXCL17 is highly expressed in many cancers, including colon can cer, it is likely to be an important chemokine for mucosal tumours and mucosal immunity 165 .
Direct antitumour effects of chemokines. Dying can cer cells can be immunogenic and can direct the anti tumour immune response. CXCL8, for example, can increase the immunogenicity of dying cancer cells by translocating calreticulin to the cell surface 166 . Calreticulin exposure on the cell surface increases the immunogenicity of the cell, and thus promotes the phagocytosis of these cells and antitumour immune responses to the tumour 167 . CXCL9 and CXCL10 are endogenous tumour angiogenesis inhibitors 168, 169 . CXCL10 prevents both CXCL8induced and basic fibroblast growth factorinduced angiogenesis in vivo and in vitro 170, 171 . 
Regulation of chemokine expression in tumours
Chemokine expression is regulated by cancer intrinsic genetic and epigenetic mechanisms and by environmental cues in the tumour microenvironment.
Epigenetic and oncogenic regulation of chemokine expression. The role of oncogenic genetic and epi genetic pathways is extensively studied in cancer biol ogy. Interestingly, recent studies have shown that in human ovarian cancer and colon cancer, the PRC2 complex, the H3K27me3 demethylase JMJD3 (also known as KDM6B) and DNA methylation repress the expression of T H 1type chemokines in tumours and prevent the trafficking of effector T cells into the tumour micro environment 172, 173 . Pharmacological and genetic interventions that increase T H 1type chemokine production lead to increased effector T cell trafficking into tumours, and improve the therapeutic efficacy of PDL1 blockade and T cell transfusion in preclinical models 172, 173 . CXCL14 expression is also reported to be repressed in lung cancer cells by DNA methylation, and forced expression of CXCL14 leads to reduced tumour growth 174 . Furthermore, human melanoma tissues that show little T cell infiltration display active β catenin sig nalling 175 . In a genetically engineered mouse melanoma model, βcatenin activation results in poor expression of CCL4 -a chemokine that is essential for CD103 + DC migration -and subsequently limits DCmediated effector T cell activation and expansion within the tumour 175 . Another epigenetic repressor, histone deacetylase 1 (HDAC1) can interact with the nuclear factorκB (NFκB) subunit p65 (also known as RELA) and repress CXCL8 expression 176, 177 . Genetic regulation, mainly mutations, can influence chemokine receptor expression and function. A point mutation has been identified in CXCR4 (G574A) in a melanoma cell line and a colon cancer cell line 178 . This mutation is functionally active, and the mutant receptor signals and traffics in response to CXCL12, but when tumours expressing this mutant receptor were allowed to grow in vivo, tumour growth was delayed 178 . Indirectly, a common gene fusion of PAX3 (which encodes paired box 3) and FKHR (which encodes forkhead homo logue in rhabdomyosarcoma; also known as FOXO1) in rhabdomyosarcoma is associated with higher CXCR4 expression 179 . Transfer of this gene fusion leads to higher CXCR4 expression in embryonic rhabdomyo sarcoma cells and increases invasion in vitro 179 . Both of these studies indicate the diverse roles of the chemokine receptor CXCR4. Thus, tumourintrinsic oncogenic 175 and epigenetic 172, 173 pathways control chemokine expres sion, and influence immune cell activation in and/or migration into the tumour microenvironment.
Both PRC2mediated epigenetic silencing 180 and βcatenin signalling are tumourintrinsic tumorigenic mechanisms, and are associated with cancer EMT and a stem celllike biological phenotype. Interestingly, these tumourintrinsic mechanisms can regulate chemokine expression and control immune cell infil tration into tumours. Based on having either relatively high or low immune cell infiltration, tumours may be immunologically classified into 'hot' (inflamed) or 'cold' (noninflamed) phenotypes, respectively. Thus, onco genic genetic and epigenetic pathways simultaneously define the biological and immunological phenotypes of the tumour, affect tumour progression, and alter spon taneous and therapyinduced tumourspecific T cell immunity (FIG. 4) . The manipulation of these tumour intrinsic pathways may promote the infiltration of T cells into tumours, alter tumour immune phenotype and ultimately lead to tumour regression.
Hypoxia and chemokine expression in tumours.
Hypoxia is a general phenomenon in the cancer microenvironment. The transcription factor hypoxia inducible factor 1 (HIF1; which comprises HIF1α and HIF1β) is the central mediator of the cellular response to hypoxia 181 . Hypoxia triggers CXCL12 expression in primary human ovarian tumour cells 26 , fibroblasts 182 and haematopoietic stem cells (HSCs) 183 . In the pro moter region of the CXCL12 gene, there are two poten tial HIF1binding sites (HBSs) termed HBS1 and HBS2 (REF. 183 ). The HBS1 region may be responsible for the HIF1dependent induction of CXCL12 synthesis 183 . Hypoxia also promotes CXCR4 expression in TAMs and tumour cells 184, 185 . In renal cell carcinoma, the mechanism of CXCR4 upregulation involves mutation of the tumoursuppressor gene VHL (which encodes von Hippel-Lindau protein) 185 . Increased CXCR4 expres sion and migration towards CXCL12 are dependent on HIF1α activation and CXCR4 transcript stabiliza tion 184, 185 . As well as inducing the expression of CXCR4 and CXCL12, hypoxia can induce CXCR7 expression in rhabdomyosarcoma cells 186 . In addition, CCL2 also has HBSs in its promoter, and hypoxia has been found to induce CCL2 expression in human astrocytes 187 and CXCL8 expression in ovarian cancer cells 188 . Thus, hypoxia can affect tumour immunity and biology by regulating the expression of several chemokines and chemokine receptors.
Metabolic regulation of chemokine expression in the tumour microenvironment. Aerobic glycolysis is a fea ture of cancer cell metabolism. In aerobic glycolysis, cancer cells produce lactic acid, which activates NFκB and induces CXCL8 expression in vascular endothelial cells, resulting in angiogenesis in breast and colon can cer 189 . In breast cancer cells, reactive oxygen species can upregulate CXCL14 expression through the transcrip tion factor activator protein 1 (AP1), thus increasing cell invasion and motility 190 . Hormones can also regulate chemokine expression. In breast cancer cells, oestrogen can upregulate the expression of CXCR4 and CXCL12 and downregulate that of CXCR7 (REF. 191) . Further studies will determine how cancer metabolism affects the expression of different chemokines in the tumour microenvironment.
The microbiota and tumour chemokine expression. Different bacteria can negatively and positively influence tumour growth. The microbiota and its by products can modulate the tumour immune response 192, 193 . These bacteria can recruit specific immune cell sub sets, thus shaping tumour growth. For example, Fusobacterium nucleatum accelerates intestinal tumours, in part by increasing the infiltration of myeloid cells that suppress T cell activity into the tumours 194 . The bind ing of shortchain fatty acids from microorganisms to G proteincoupled receptor 43 (GPR43) leads to inflam mation resolution in mouse models. GPR43deficient mice have high levels of inflammation and immune cell recruitment, and an exacerbated immune response 195 . Another bacterium, Faecalibacterium prausnitzii, is an antiinflammatory commensal bacterium that decreases in abundance in patients with Crohn's disease 196, 197 . Its metabolites block NFκB activation and CXCL8 pro duction 196, 197 . Thus, although there is no direct evidence of microbiotainduced regulation of chemokine expres sion in tumours, the microbiota and its byproducts are presumably involved in tumour immune responses in specific types of human cancers such as colon cancer.
Chemokines and cancer immunotherapy
Given that chemokines and their receptors have cru cial roles in inflammatory human diseases, efforts have been made to target chemokine networks in patients with autoimmune diseases and chronic inflammation.
Drugs that target CCR5 (namely, maraviroc) and CXCR4 (namely, plerixafor; also known as AMD3100 and mar keted as Mozobil by Genzyme) have been approved for use in HIV infection and for the mobilization of HSCs for transplantation, respectively. However, the target ing of chemokines and chemokine receptors has so far failed to yield any viable antiinflammatory drugs. As discussed above, the chemokines CCL2, CCL3, CCL5, CXCL8, CXCL9, CXCL10 and CXCL12 are rel atively well studied in human cancer. Below, we focus on the potential of targeting these chemokines and their receptors to promote antitumour immune responses in patients with cancer, and we discuss the possibility of combining chemokinebased therapies with current cancer immunotherapies.
CXCL9 and CXCL10.
Poor tumour infiltration by T cells has been attributed to potent epigenetic silencing of the genes encoding the T H 1type chemokines CXCL9 and CXCL10 in tumours 172, 173 . As discussed above, these chemokines promote the migration of effector T cells and NK cells into tumours. Studies have shown that improved therapeutic responses to cancer immuno therapy and chemotherapy are associated with increased levels of T H 1type chemokines and increased numbers of effector T cells in the tumour microenvironment 10, 198 . Thus, cancer epigenetic reprogramming may remove the epigenetic repression of genes encoding T H 1type chemokines, thus promoting effector T cell trafficking into the tumour microenvironment and improving the therapeutic efficacy of immunotherapy. In support of this, treatment with cancer epigenetic re programming drugs -including EZH2 inhibitors, DZNep 199 , a selective inhibitor of EZH2 methyltransferase activity (GSK126) 200 or a DNMT inhibitor (5aza2′ deoxycytidine) -increases tumour T H 1type chemo kine production and T cell trafficking into tumours 172, 173 , and augments the therapeutic effects of PDL1 blockade and T cell therapy in a preclinical model 172 . Furthermore, treatment with azacitidine upregulates the expres sion of IFN signature genes in several human can cer cell lines 201, 202 . 5aza2′deoxycytidine treatment increases the expression of the cancer and germline TAA NYESO1 (also known as cancer/testis anti gen 1) in human ovarian cancer cells 203 , and promotes chemo kine expression and T cell tumour trafficking in a mouse ovarian cancer model 198 . Thus, epigenetic re programming can derepress the repressed T H 1type chemokineencoding genes, and promote the expression of IFN signature genes and TAAs, and may thus promote T cell infiltration into tumours and ultimately potentiate PDL1 and PD1 blockade therapy 172, 173, 198 . CXCL12 and CXCR4. CXCL12-CXCR4 signalling is implicated in immune cell tumour trafficking and tumour cell biology. CXCL12-CXCR4 signalling medi ates plasmacytoid DC trafficking into tumours 25 and T reg cell homing to the bone marrow microenviron ment 41, 42 , and is involved in tumour cell proliferation 63 , metastasis 138 and tumour vascularization 26 . AMD3100 is a CXCR4 antagonist and has been used in human clinical trials for the treatment of HIV infection 204 . The blockade of CXCR4-CXCL12 signalling may reduce tumour angiogenesis, invasiveness and tumour induced immunosuppression. Indeed, antiCXCR4 and antiCXCL12 antibodies each prevented metas tasis, reduced tumour weight and prevented tumour extravasation in preclinical models 138, [205] [206] [207] [208] . Thus, it is tempting to speculate that the administration of antagonists of CXCR4-CXCL12 signalling could be therapeutically beneficial in combination with current immunotherapies. A clinical trial is now underway to evaluate the safety of combinatorial immunotherapy with the CXCR4 peptide antagonist LY2510924 and the antiPDL1 antibody durvalumab 209 .
CXCL8 and CXCR1. CXCL8-CXCR1 signalling is involved in tumour angiogenesis, tumour stemness and inflammatory immune cell trafficking into the tumour microenvironment 91 . Strategies that aim to interfere with this chemokine regulatory loop may represent a strategy for targeting the cancer microenvironment. Repertaxin (also known as reparixin) is a noncompetitive allosteric inhibitor of CXCR1 and CXCR2. Repertaxin was origi nally developed to block CXCL8 activity, and thus reduce tissue damage after myocardial infarction or stroke 210 .
A phase I clinical trial has demonstrated that reper taxin is well tolerated in healthy volunteers 211 . Further clinical trials are needed to determine the safety and efficacy of repertaxin in combination with current immunotherapies in patients with cancer.
CCL2, CCL3 and CCL5. These chemokines are impli cated in macrophage and neutrophil recruitment into the tumour microenvironment. CCL5 promotes ovar ian cancer stemlike properties 101, 102 . CCL2, CCL3 and CCL5 may bind to CCR1, CCR2, CCR3 and CCR5. Targeting these chemokine receptors may prevent the accumulation of immunosuppressive myeloid cell in tumours. Indeed, targeting CCL2, CCL3 or CCL5 sig nalling inhibits metastasis and angiogenesis in mouse models of breast cancer, lung cancer and ovarian can cer 66, 74, 96, 101 . However, the cessation of CCL2 neutra lization monotherapy leads to increased metastasis and rapid death in mouse models of breast cancer 96 . Thus, CCL2 blockade may need to be combined with other immunotherapies to increase the antitumour response and avoid the potential detrimental effect of singlechemokine blockade. For example, CCL2 block ade synergistically improves the cancer vaccine response in mouse models of lung cancer and mesothelioma 212 . Macrophage depletion increases the therapeutic efficacy of anticytotoxic T lymphocyte antigen 4 (CTLA4) and antiPD1 antibodies in mouse pancreatic cancer mod els 213 . Given that different subsets of macrophages may be functionally different, clinical studies are needed to determine whether macrophage depletion can yield an antitumour response. Indeed, a phase II clinical trial has been conducted using MLN1202, an antiCCR2 mon oclonal antibody, in patients with cancer bone meta stasis 214 . In addition, Chemocentryx recently initiated a phase Ib trial of a CCR2 antagonist (CCX872) in patients with nonresectable pancreatic cancer 215 . These clinical studies will provide the mostneeded information on the safety and potential therapeutic efficacy of CCR2 signalling blockade in patients with cancer.
Concluding remarks
Chemokines and chemokine receptors mediate immune cell trafficking into the tumour micro environment. Different immune cell subsets differentially contrib ute to cancer progression and therapy. The genes that encode T H 1type chemokines are repressed by epige netic mechanisms in cancer, and this affects the num bers of antitumour effector immune cells that are present within tumours, determines the cancer immune pheno type, and shapes the therapeutic efficacy of immune checkpoint blockade, adoptive T cell therapy and con ventional therapy 10, 172, 173 . By contrast, the chemokines associated with the tumour trafficking of myeloid cells, T reg cells and T H 22 cells can directly and indirectly influence the biological phenotype of a tumour (for example, whether it is a stem/EMTtype or nonstem/ EMTtype tumour) 30, 34, 43, 73, 86 . Thus, direct and indirect manipulation of chemokine-chemokine receptor signal ling pathways may reshape the immune and biological phenotypes of a tumour in a manner that increases the therapeutic efficacy of immunotherapy. Of note, clini cal trials of agents that directly target a single chemo kine or chemokine receptor have not yielded impressive therapeutic efficacy in patients with chronic inflamma tory diseases such as AIDS, diabetes and rheumatoid arthritis. One reason for this is that chemokines gener ally bind to multiple receptors. These ligands may then activate alternative receptors, abrogating the effect of the single antagonist or blocker. Furthermore, therapies that target specific chemokines or chemokine recep tors can affect the trafficking of different immune cell subsets into tumours and alter the biological activities of nonimmune cells in the tumour microenvironment. Hence, similarly to what is seen in chronic inflamma tory diseases, a therapeutic strategy of directly targeting a single chemokine or chemokine receptor may not achieve a meaningful clinical response. Based on current find ings and the above discussion, it is predicted that directly targeting both protumour and antitumour chemokinechemokine receptor signalling pathways 10, 172, 173 in com bination with other immunotherapies could achieve clinical benefits in patients with cancer. Further studies in preclinical models and patients are required to bring this combination approach into clinical application.
1.
Rot 
